Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
51.1M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
43.8M
-
Shares change
-
+1.37M
-
Total reported value, excl. options
-
$512M
-
Value change
-
+$8.07M
-
Put/Call ratio
-
1.03
-
Number of buys
-
96
-
Number of sells
-
-74
-
Price
-
$11.70
Significant Holders of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) as of Q2 2024
217 filings reported holding RGNX - REGENXBIO Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.8M shares
of 51.1M outstanding shares and own 85.63% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.61M shares), VANGUARD GROUP INC (5.11M shares), Redmile Group, LLC (4.57M shares), JPMORGAN CHASE & CO (3.01M shares), STATE STREET CORP (2.87M shares), Avidity Partners Management LP (1.3M shares), MORGAN STANLEY (1.18M shares), DIMENSIONAL FUND ADVISORS LP (1.11M shares), GEODE CAPITAL MANAGEMENT, LLC (1.04M shares), and Integral Health Asset Management, LLC (950K shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.